177lu-psma-617
novartis
['pcsm', '177lu,psma,617', 'prostate']
data presented at 2022 asco reveals pet-imaging characteristics linked with 177lu-psma-617 efficacy in metastatic castration-resistant prostate cancer. #pcsm #asco22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.